Cardarine
Cardarine (GW-501516)
100 tabs × 20 mg/tab
Coming soon
View details Cardarine (GW-501516) →Product photograph of the current pack. Each physical unit carries the same blue-teal ZX label artwork, a batch code and a scratch-off verification panel.
Selective Androgen Receptor Modulators
Testolone
Independent batch results for Testolone (RAD 140) are not yet published. They will be added here once testing is complete.
Product information
15 mg per tablet · 100 tablets · Zyvex Pharmaceuticals
Testolone (RAD 140) from Zyvex Pharmaceuticals contains testolone (RAD-140) at 15 mg per tablet and comes in a pack of 100 tablets.
This prospect summarises composition, clinical considerations and handling. It supports professional review and does not replace an individual prescription or verified instructions for the exact preparation.
Testolone (RAD 140) is the product name used by Zyvex Pharmaceuticals. The ingredient discussed in the following sections is testolone (RAD-140), classified as a selective androgen receptor modulator.
| Property | Details |
|---|---|
| Product name | Testolone (RAD 140) |
| Manufacturer | Zyvex Pharmaceuticals |
| Active ingredient | Testolone |
| Strength | 15 mg per tablet |
| Package | 100 tablets |
| Drug class | Selective androgen receptor modulator |
| Chemical formula | C20H16ClN5O2 |
| Dosage form and route | Tablet; oral |
A solid tablet for oral administration. Each tablet provides a measured amount of active ingredient. Confirm suitability with a pharmacist before splitting or crushing; appearance and score lines alone do not establish accurate dose division.
Testolone (RAD 140) from Zyvex Pharmaceuticals contains testolone. Testolone, also called RAD-140, is a selective androgen receptor modulator investigated in advanced hormone-receptor-positive breast cancer. That oncology research does not establish routine treatment for healthy people seeking more muscle.
People use testolone as a workout or physique-enhancement compound. Published clinical reports also describe liver injury associated with its use.
A first-in-human oncology trial evaluated 50, 100 or 150 mg orally once daily in postmenopausal women with metastatic breast cancer. These cancer-study doses are not bodybuilding doses or a safe upper limit. No standard performance-enhancement protocol follows from that trial.
A reliable routine human dosing regimen cannot be established from the available clinical evidence. The product strength must not be converted into a self-treatment schedule. Human use requires an appropriately supervised clinical or research setting with a defined protocol. Research dosing is protocol-specific and should not be converted into a bodybuilding or post-cycle schedule.
A complete clinical contraindication profile has not been established. Avoid exposure with known hypersensitivity, during pregnancy or breastfeeding, and in children outside a properly reviewed clinical setting. Absence of a listed contraindication is not evidence of safety.
Potential concerns include liver injury, changes in lipids and suppression of normal hormone production. The term "selective" does not mean that effects are limited to muscle. Seek assessment for jaundice, dark urine, persistent itching or severe fatigue.
Human interaction studies are limited. A clinician or study team should review all prescription medicines, nonprescription products and supplements. There is no basis for assuming that combinations with other experimental compounds are safe. Other androgens or compounds that affect the liver may add to clinical risk.
Adequate pregnancy, lactation and reproductive safety evidence is lacking. Avoid exposure during pregnancy or breastfeeding. Any reproductive-risk precautions in a clinical study should be directed by the study team.
Human reports include clinically important liver injury. Case reports help identify possible harm but cannot establish how frequently it occurs or validate a 15 mg self-treatment regimen. A dependable frequency category cannot be assigned to all potential reactions.
For a suspected overdose, contact a poison-information service or urgent medical care and provide the product, amount, time and other substances taken. Collapse, seizures or breathing difficulty require emergency help. Do not induce vomiting or attempt an antidote at home. Clinical treatment depends on symptoms and the substances involved.
Testolone (RAD-140) is a nonsteroidal androgen-receptor modulator. Receptor activation can affect androgen-responsive tissues and hormonal feedback; the desired tissue selectivity is not proof of clinical safety.
Human studies describe exposure under particular trial conditions. Their results do not demonstrate bioequivalence for a different tablet preparation. A dosing interval should not be inferred solely from a reported half-life.
Keep tablets sealed in the original container, protected from excessive heat, moisture and accidental access. Use storage and expiry conditions supported by the finished preparation's stability information. A laboratory compound's storage temperature does not establish appropriate medicinal tablet storage. Arrange disposal through a pharmacy or supervising research service.
Browse more
Cardarine
100 tabs × 20 mg/tab
Coming soon
View details Cardarine (GW-501516) →